JP2016538271A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538271A5 JP2016538271A5 JP2016526337A JP2016526337A JP2016538271A5 JP 2016538271 A5 JP2016538271 A5 JP 2016538271A5 JP 2016526337 A JP2016526337 A JP 2016526337A JP 2016526337 A JP2016526337 A JP 2016526337A JP 2016538271 A5 JP2016538271 A5 JP 2016538271A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- salt
- nicotinamide riboside
- weight
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 58
- 235000020956 nicotinamide riboside Nutrition 0.000 claims 14
- 239000011618 nicotinamide riboside Substances 0.000 claims 14
- -1 nicotinamide riboside compound Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 6
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 6
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 claims 6
- 210000003491 skin Anatomy 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 3
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims 3
- 229910002651 NO3 Inorganic materials 0.000 claims 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
- 229940072107 ascorbate Drugs 0.000 claims 3
- 235000010323 ascorbic acid Nutrition 0.000 claims 3
- 239000011668 ascorbic acid Substances 0.000 claims 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 3
- 150000003841 chloride salts Chemical class 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000001177 diphosphate Substances 0.000 claims 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 3
- 235000011180 diphosphates Nutrition 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229940044170 formate Drugs 0.000 claims 3
- 229940050410 gluconate Drugs 0.000 claims 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 3
- 229940001447 lactate Drugs 0.000 claims 3
- 229940102396 methyl bromide Drugs 0.000 claims 3
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 3
- 230000005778 DNA damage Effects 0.000 claims 2
- 231100000277 DNA damage Toxicity 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361897713P | 2013-10-30 | 2013-10-30 | |
| US61/897,713 | 2013-10-30 | ||
| PCT/US2014/063260 WO2015066382A1 (en) | 2013-10-30 | 2014-10-30 | Nicotinamide riboside compositions for topical use in treating skin conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538271A JP2016538271A (ja) | 2016-12-08 |
| JP2016538271A5 true JP2016538271A5 (enExample) | 2017-12-21 |
| JP6509844B2 JP6509844B2 (ja) | 2019-05-08 |
Family
ID=53005146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526337A Active JP6509844B2 (ja) | 2013-10-30 | 2014-10-30 | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10688118B2 (enExample) |
| EP (1) | EP3063163B1 (enExample) |
| JP (1) | JP6509844B2 (enExample) |
| KR (3) | KR20160067195A (enExample) |
| CN (2) | CN105873937A (enExample) |
| AU (1) | AU2014342185B2 (enExample) |
| CA (1) | CA2928656C (enExample) |
| ES (1) | ES2925879T3 (enExample) |
| MX (2) | MX394291B (enExample) |
| NZ (1) | NZ719328A (enExample) |
| WO (1) | WO2015066382A1 (enExample) |
| ZA (1) | ZA201603314B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3149016A1 (en) | 2014-06-02 | 2017-04-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-d-nicotinamide riboside |
| US10485814B2 (en) | 2014-06-06 | 2019-11-26 | Glaxosmithkline Intellectual Property (No. 2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| KR102629310B1 (ko) | 2015-03-09 | 2024-01-24 | 더블유.알. 그레이스 앤드 캄파니-콘. | 니코틴아미드 리보사이드의 결정 형태 |
| WO2016149395A1 (en) * | 2015-03-16 | 2016-09-22 | ChromaDex Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
| EP3288530A1 (en) | 2015-05-01 | 2018-03-07 | The Procter and Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
| JP2018515486A (ja) | 2015-05-01 | 2018-06-14 | ザ プロクター アンド ギャンブル カンパニー | ニコチンアミドリボシドを用いた皮膚外観の改善方法及びそのための組成物 |
| EP3288531B1 (en) * | 2015-05-01 | 2019-07-24 | The Procter and Gamble Company | Method of improving skin health and compositions therefor |
| ES2932801T3 (es) | 2015-06-10 | 2023-01-26 | Elysium Health Inc | Composiciones de ribósido de nicotinamida y pterostilbeno y métodos para el tratamiento de trastornos de la piel |
| WO2016210232A1 (en) * | 2015-06-25 | 2016-12-29 | N.V. Perricone Llc | Niacinamide mononucleotide formulations for skin aging |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| WO2017004100A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Encapsulated particles comprising nicotinamide riboside |
| US20160374908A1 (en) | 2015-06-29 | 2016-12-29 | The Procter & Gamble Company | Skin care composition and methods of using the same |
| EP3236928B1 (en) | 2016-01-11 | 2020-12-09 | The Procter and Gamble Company | Method of treating a skin condition and compositions therefor |
| US10000520B2 (en) | 2016-03-16 | 2018-06-19 | ChromaDex Inc. | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof |
| EP3445359B8 (en) | 2016-04-20 | 2023-09-06 | Chromadex Inc. | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+ increasing precursors |
| CN109982706A (zh) * | 2016-08-22 | 2019-07-05 | 益力舒健康公司 | 用于治疗神经退行性病症的烟酰胺核苷和紫檀芪的组合物和方法 |
| CN120463761A (zh) | 2016-11-11 | 2025-08-12 | 英国贝尔法斯特女王大学 | 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成 |
| US11633421B2 (en) | 2016-11-29 | 2023-04-25 | University Of Iowa Research Foundation | Use of NAD precursors for improving maternal health and/or offspring health |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| WO2018114745A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions comprising poorly soluble compounds |
| EA201991185A1 (ru) | 2016-12-21 | 2020-01-13 | Юнилевер Н.В. | Композиции для личной гигиены, содержащие цистин |
| EP3558255B1 (en) | 2016-12-21 | 2021-10-13 | Unilever IP Holdings B.V. | Topical skin lightening additive and composition with amino acids and nicotinamide compounds |
| US11260005B2 (en) | 2016-12-21 | 2022-03-01 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
| RU2651047C1 (ru) * | 2017-05-04 | 2018-04-18 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Лекарственная композиция цитопротекторного действия и способ ее получения |
| EP3624808A4 (en) * | 2017-05-18 | 2021-03-03 | Elysium Health, Inc. | PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP |
| EP3642214A2 (en) | 2017-06-19 | 2020-04-29 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| JP6997222B2 (ja) | 2017-06-23 | 2022-01-17 | ザ プロクター アンド ギャンブル カンパニー | 皮膚の外観を改善するための組成物及び方法 |
| CN111542312A (zh) | 2017-07-28 | 2020-08-14 | 老龄化控制中心股份公司 | 预防和逆转衰老方面的组合物和方法 |
| EP3682746A4 (en) * | 2017-09-14 | 2021-03-10 | Megumi Tanaka | AGING PROTECTION AGENTS AND AGING PROTECTION PROCEDURES |
| GB201716391D0 (en) * | 2017-10-06 | 2017-11-22 | Xobaderm Ltd | Kit for delivery of an active compound into a biological barrier |
| CN112020363A (zh) | 2017-12-22 | 2020-12-01 | 益力舒健康公司 | 烟酰胺核苷氯化物的结晶形式 |
| WO2020010036A1 (en) | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
| CN110913864B (zh) * | 2018-08-17 | 2022-12-13 | 邦泰生物工程(深圳)有限公司 | 一种稳定型烟酰胺核糖组合物及其制备方法 |
| KR102060374B1 (ko) * | 2018-12-14 | 2019-12-30 | 주식회사 휴메딕스 | 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체 |
| US11833167B2 (en) | 2018-12-17 | 2023-12-05 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CA3148300A1 (en) | 2019-07-19 | 2021-01-28 | Biosynth Ag | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof |
| CN110638827A (zh) * | 2019-10-17 | 2020-01-03 | 泓博元生命科技（深圳）有限公司 | Nadh及其盐在制备皮肤色素抑制剂中的应用 |
| CN111166760A (zh) * | 2019-12-17 | 2020-05-19 | 浙江安赛新材料科技有限公司 | β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用 |
| KR102315139B1 (ko) | 2019-12-17 | 2021-10-20 | 주식회사 휴메딕스 | 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체 |
| CN111184732B (zh) * | 2020-03-04 | 2023-09-08 | 武汉华纳联合药业有限公司 | 一种复合组合物制剂及其制备方法和皮肤炎症中的应用 |
| CN111454311B (zh) * | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
| FR3110410A1 (fr) * | 2020-05-20 | 2021-11-26 | Nuvamid Sa | Compositions cosmétiques anti-âge comprenant de la NMN |
| WO2021234009A1 (fr) * | 2020-05-20 | 2021-11-25 | Nuvamid Sa | Compositions cosmetiques anti-age comprenant du nmn |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| WO2021247496A1 (en) | 2020-06-01 | 2021-12-09 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
| CN111632049A (zh) * | 2020-06-09 | 2020-09-08 | 西北农林科技大学 | 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方 |
| US20230263817A1 (en) * | 2020-08-28 | 2023-08-24 | University Of Washington | High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation |
| WO2022157173A1 (en) * | 2021-01-19 | 2022-07-28 | Biosynth Ag | Method of making nicotinamide ribofuranoside salts by salt metathesis, the crystalline form of its tosylate salt and the co-crystallized form of its chloride:iodide salt |
| EP4333807A1 (en) * | 2021-05-04 | 2024-03-13 | Sovida Solutions Ltd. | Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof |
| CN114129509B (zh) * | 2021-12-03 | 2023-12-01 | 药酚享科技(北京)有限公司 | 一种保湿性nmn亲水凝胶剂及其制备方法 |
| CN116621898A (zh) * | 2022-04-13 | 2023-08-22 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途 |
| KR102784901B1 (ko) * | 2022-06-23 | 2025-03-21 | 제너럴바이오(주) | Nr, nmn 및 nad를 함유한 피부 주름 개선용 화장료 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200305174B (en) * | 2001-02-22 | 2004-09-23 | Unilever Plc | Skin composition for reducing skin oils and grease. |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| JP2007521835A (ja) | 2004-02-10 | 2007-08-09 | トラスティーズ・オブ・ダートマウス・カレッジ | ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法 |
| JP2008501343A (ja) | 2004-06-04 | 2008-01-24 | ワシントン・ユニバーシティ | 神経障害を治療するための方法および組成物 |
| EP2805719A1 (en) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| CN101257897A (zh) * | 2005-07-07 | 2008-09-03 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
| AU2006269459B2 (en) * | 2005-07-07 | 2013-02-07 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| EP1957086B1 (en) | 2005-11-18 | 2018-05-02 | Cornell Research Foundation, Inc. | Nicotinoyl riboside compositions and methods of use |
| US20100105638A1 (en) * | 2007-03-12 | 2010-04-29 | Kerstin Den-Braven | Cosmetic compositions |
| US20090069444A1 (en) | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
| JP5688376B2 (ja) * | 2010-01-06 | 2015-03-25 | 株式会社ヤクルト本社 | 経口用のｄｎａ損傷修復促進剤及びエラスターゼ活性抑制剤 |
-
2014
- 2014-10-30 ES ES14857903T patent/ES2925879T3/es active Active
- 2014-10-30 CN CN201480071722.4A patent/CN105873937A/zh active Pending
- 2014-10-30 MX MX2021009652A patent/MX394291B/es unknown
- 2014-10-30 US US15/033,285 patent/US10688118B2/en active Active
- 2014-10-30 KR KR1020167014302A patent/KR20160067195A/ko not_active Ceased
- 2014-10-30 CN CN201910027571.7A patent/CN109985056A/zh active Pending
- 2014-10-30 MX MX2016005574A patent/MX385305B/es unknown
- 2014-10-30 CA CA2928656A patent/CA2928656C/en active Active
- 2014-10-30 AU AU2014342185A patent/AU2014342185B2/en active Active
- 2014-10-30 KR KR1020227022241A patent/KR20220098049A/ko not_active Ceased
- 2014-10-30 EP EP14857903.0A patent/EP3063163B1/en active Active
- 2014-10-30 JP JP2016526337A patent/JP6509844B2/ja active Active
- 2014-10-30 KR KR1020217026414A patent/KR20210107895A/ko not_active Ceased
- 2014-10-30 NZ NZ719328A patent/NZ719328A/en unknown
- 2014-10-30 WO PCT/US2014/063260 patent/WO2015066382A1/en not_active Ceased
-
2016
- 2016-05-16 ZA ZA2016/03314A patent/ZA201603314B/en unknown
-
2020
- 2020-06-03 US US16/891,824 patent/US11033568B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538271A5 (enExample) | ||
| IN2014MN02288A (enExample) | ||
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| IN2014MN01755A (enExample) | ||
| NZ726366A (en) | Syk inhibitors | |
| JP2016147915A5 (enExample) | ||
| MX2014008021A (es) | Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| MX2016009063A (es) | Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| JP2013530208A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| JP2014530204A5 (enExample) | ||
| JP2013525342A5 (enExample) | ||
| JP2017525738A5 (enExample) | ||
| JP2017513944A5 (enExample) | ||
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| PH12015502203A1 (en) | Phenyl derivative | |
| JP2011157392A5 (enExample) | ||
| DK2004235T3 (da) | Sammensætning til kosmetisk eller farmaceutisk-dermatologisk anvendelse | |
| MX2014011843A (es) | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. | |
| RU2016115716A (ru) | Атимикробные наночастицы диоксида титана, модифицированные катионами серебра | |
| JP2014508170A5 (enExample) |